ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Renal Cell Carcinoma
RENAL CELL CARCINOMA ADVISOR
FEATURED CONTENT
-
-
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care. -
On the Radar for RCC in 2021: McGregor Discusses Combination Strategies, HIF-2α Inhibition, and Other Key Topics
Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021. -
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021. -
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
VIDEO SERIES
Tivozanib for RCC
Genitourinary Oncology: A Peek Over the Horizon
Immunotherapy of Renal Cell Carcinoma
Targeted Therapies for Renal Cell Carcinoma
Genetics and Heterogeneity
Genetic Predisposition to Kidney Cancers
Personalized Medicines for Kidney Cancers
Drugs in the Pipeline
Resistance to Therapy Among Kidney Cancers
Targeted Therapy
The Role of Neoadjuvant Tx
Sx Options – Ablative Techniques
Sx Options – Lymph Node
Sx Options – Cytoreductive Nephrectomy
TKIs – First-Line Therapy
TKIs – Second-Line Therapy
Biomarkers in RCC
The MET Pathway
Checkpoint Inhibitors
RENAL CELL CARCINOMA NEWS
Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Renal Cell Carcinoma
